Undervalued Biotechnology Stocks on NYS April 2025

April 13, 2025

Biotechnology

Biotechnology and Biopharmaceutical companies are engaged in research, discovery, development, and production of innovative drug and drug-related technologies.

New York Stock Exchange

The New York Stock Exchange, located in New York City, is the largest securities exchange in the world by market capitalization of its listed companies.

Our Valuation

A stock is considered undervalued if it trades at a discount to our valuation. To determine a stock’s intrinsic value, we developed an algorithm that uses 6 valuation models to determine the value of a company.* To learn more about stockcalc’s valuation methods, click here.

Undervalued Biotechnology stocks

Stocks in this category are held primarily for capital appreciation.

For an in-depth look at the fundamentals and valuation of each company, try the stockcalc platform free for 30 days.

SymbolNameClose Price ($)Valuation ($)Difference (%)Average Vol (30D)Market Cap ($M)Yield (%)P/E Ratio
ADCT ADC Therapeutics 1.22 4.07 233.88 396173 119 0.00 0.0
ANVS Annovis Bio 1.30 3.42 162.87 254482 16 0.00 0.0
RCUS Arcus Biosciences 8.18 9.10 11.26 1076197 737 0.00 0.0
ANRO Alto Neuroscience 2.13 2.14 0.48 314031 52 0.00 0.0
All data provided as at market close April 10, 2025.

Company Details

ADC Therapeutics

ADCT:NYS

Close Price

1.22

Our Valuation

4.07

% Difference

233.88

Market Cap ($M)

119

P/E Ratio

0.0

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.

Access the stockcalc valuation


Annovis Bio

ANVS:NYS

Close Price

1.30

Our Valuation

3.42

% Difference

162.87

Market Cap ($M)

16

P/E Ratio

0.0

Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.

Access the stockcalc valuation


Arcus Biosciences

RCUS:NYS

Close Price

8.18

Our Valuation

9.10

% Difference

11.26

Market Cap ($M)

737

P/E Ratio

0.0

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others.

Access the stockcalc valuation


Alto Neuroscience

ANRO:NYS

Close Price

2.13

Our Valuation

2.14

% Difference

0.48

Market Cap ($M)

52

P/E Ratio

0.0

Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.

Access the stockcalc valuation


ADC Therapeutics and Annovis Bio are the most undervalued Biotechnology stocks on the NYS. See the full list on the blog: https://www.stockcalc.com/Blog/undervalued-biotechnology-stocks-nys-april-2025
ADC Therapeutics $ADCT and Annovis Bio $ANVS are the most undervalued Biotechnology stocks on the #NYS. See the full list: https://www.stockcalc.com/Blog/undervalued-biotechnology-stocks-nys-april-2025
ADC Therapeutics and Annovis Bio are the most undervalued Biotechnology stocks on the NYS. See the full list on the blog: https://www.stockcalc.com/Blog/undervalued-biotechnology-stocks-nys-april-2025

Copyright © 2016- Patchell Brook Equity Analytics Inc. All rights reserved.

Risk Disclosure: Equities trading and trading of all markets, exchanges and instruments contains substantial risk and is not for every investor. An investor could potentially lose all or more than the initial investment. Risk capital is money that can be lost without jeopardizing ones’ financial security or life style. Only risk capital should be used for trading and only those with sufficient risk capital should consider trading. Past performance is not necessarily indicative of future results. View full risk information here.